Level 1 — Absolute Beginner
Eli Lilly is a big drug company. This week, it became worth one trillion dollars. No drug company has ever been worth this much money.
The company makes two popular drugs. One is called Mounjaro. It helps people with diabetes. The other is called Zepbound. It helps people lose weight.
Many people want these drugs. This week, Eli Lilly said it made more money than experts expected. The stock price went up a lot.
Eli Lilly is based in Indianapolis, Indiana. The company started in 1876. It is now one of the biggest companies in the world.
- trillion
- the number 1,000,000,000,000, a very large amount
- drugmaker
- a company that makes medicine
- diabetes
- a health problem where the body has trouble controlling sugar
- weight loss
- losing extra body weight
- stock
- a small piece of a company that people can buy or sell
- earnings
- the money a company makes
- demand
- how much people want to buy something
- milestone
- an important point or achievement
Level 2 — Elementary
Eli Lilly has made history this week by becoming the first pharmaceutical company ever to reach a market value of one trillion dollars.
The company's stock jumped to a record high after it reported second-quarter earnings that beat what Wall Street analysts had expected. Lilly's revenue for the quarter reached 15.7 billion dollars.
Much of that growth came from two blockbuster drugs: Mounjaro, which treats diabetes, and Zepbound, which is used for weight loss. Sales of Zepbound in the United States alone jumped 44 percent to 4.9 billion dollars.
Because of this strong performance, Eli Lilly raised its guidance for how much money it expects to make for the whole year, now predicting revenue between 85 and 87 billion dollars, up from its earlier forecast.
- pharmaceutical
- relating to the making and selling of medicine
- market value
- the total worth of a company based on its stock price
- revenue
- the total money a company earns from selling its products
- analyst
- a person who studies companies and predicts how well they will do
- blockbuster
- extremely successful or popular
- quarter
- a three-month period used to measure a company's business results
- guidance
- a company's prediction about its future earnings
- forecast
- a prediction about what will happen in the future
Level 3 — Intermediate
Eli Lilly has become the first pharmaceutical company in history to reach a market capitalization of roughly one trillion dollars, a milestone reached this week as investors reacted to a stronger-than-expected second-quarter earnings report.
The Indianapolis-based drugmaker posted revenue of 15.7 billion dollars for the quarter, fueled overwhelmingly by demand for its GLP-1 drugs Mounjaro, which treats type 2 diabetes, and Zepbound, which is prescribed for chronic weight management. US sales of Zepbound alone climbed 44 percent year over year to 4.9 billion dollars, even as the company faced some downward pressure on prices.
Buoyed by that momentum, Lilly raised its full-year 2026 revenue guidance to a range of 85 to 87 billion dollars, up from its previous forecast of 82 to 85 billion dollars, signaling continued confidence that demand for its obesity and diabetes treatments will remain strong through the rest of the year.
The trillion-dollar valuation underscores just how dominant the GLP-1 category has become for the pharmaceutical industry, with some analysts projecting the global market for these drugs could eventually generate more than 150 billion dollars in annual sales worldwide.
- market capitalization
- the total value of a company's shares of stock, used to measure its overall worth
- GLP-1
- a class of drugs originally developed for diabetes that also help with weight loss
- chronic
- continuing for a long time, often describing a long-term medical condition
- year over year
- comparing a figure to the same period one year earlier
- downward pressure
- a force pushing prices or values lower
- momentum
- the force that keeps something moving forward or growing
- valuation
- an estimate of how much something, such as a company, is worth
- category
- a group of similar products or things
Level 4 — Advanced
Eli Lilly's ascent to a roughly trillion-dollar market capitalization this week, the first such milestone for any pharmaceutical company, crystallizes a broader reordering of corporate America in which a handful of GLP-1 therapies have reshaped not just the healthcare sector but the balance of the entire stock market.
The Indianapolis-based drugmaker's shares surged after it posted second-quarter revenue of 15.7 billion dollars, comfortably ahead of Wall Street's projections, propelled by Mounjaro and Zepbound, its diabetes and obesity franchises, respectively. Domestic Zepbound revenue alone rose 44 percent year over year to 4.9 billion dollars, a figure that would have been higher still had it not been partially offset by pricing pressure as competition intensifies and payers push back on costs.
Management's decision to lift full-year guidance to a range of 85 to 87 billion dollars, an upward revision from the previous 82-to-85-billion-dollar band, reflects not merely a strong quarter but a conviction that demand for GLP-1 therapies has yet to plateau, even as rivals race to bring competing formulations to market.
The trillion-dollar threshold is as much a symbolic marker as a financial one, reinforcing how thoroughly the GLP-1 boom has redrawn the pharmaceutical industry's competitive hierarchy; some analysts now forecast the category could generate upward of 150 billion dollars annually worldwide, a scale that invites scrutiny over drug pricing even as it cements Lilly's position as one of the most valuable companies on the planet.
- ascent
- a rise or climb to a higher level
- crystallize
- to become clear and take a definite form
- franchise
- here, a company's major product line that drives significant revenue
- offset
- to balance out or reduce the effect of something
- payer
- an organization, such as an insurer, that pays for healthcare costs
- plateau
- to stop increasing and remain at a steady level
- hierarchy
- a ranking of people or things according to status or importance
- scrutiny
- close and careful examination or criticism
Talk about this article with KatePractice this story's vocabulary in a real spoken conversation with your AI tutor